Iron citrate reduces high phosphate-induced vascular calcification by inhibiting apoptosis

Atherosclerosis

Volumn 254, Issue , 2016, Pages 93-101

  Ciceri, Paola ^a   Elli, Francesca ^a   Braidotti, Paola ^a   Falleni, Monica ^a   Tosi, Delfina ^a   Bulfamante, Gaetano ^a   Block, Geoffrey A ^b   Cozzolino, Mario ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Nephrology Department   (United States)

Author keywords

Apoptosis; Iron; Phosphate; Vascular calcification; VSMC

Indexed keywords

ALPHA ACTIN; BONE MORPHOGENETIC PROTEIN 2; CALCIUM; CHLOROQUINE; FERRIC CHLORIDE; FERRIC CITRATE; FERRIC FERROCYANIDE; FERROUS CHLORIDE; GROWTH ARREST SPECIFIC PROTEIN 6; OPN PROTEIN; PHOSPHATE; TRANSCRIPTION FACTOR RUNX2; TRANSGELIN; UNCLASSIFIED DRUG; ACTIN; BMP2 PROTEIN, RAT; CITRIC ACID; IRON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; BLOOD VESSEL CALCIFICATION; CELL DIFFERENTIATION; CELL VACUOLE; CONTROLLED STUDY; CYTOPLASM; DNA FRAGMENTATION; DOWN REGULATION; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; GENE EXPRESSION; HISTOLOGY; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASCULAR SMOOTH MUSCLE CELL; WESTERN BLOTTING; ANIMAL; CELL CULTURE; CHEMICALLY INDUCED; CHEMISTRY; CYTOLOGY; DISEASE EXACERBATION; METABOLISM; VASCULAR SMOOTH MUSCLE;

ACTINS; ANIMALS; APOPTOSIS; AUTOPHAGY; BONE MORPHOGENETIC PROTEIN 2; CALCIUM; CELL DIFFERENTIATION; CELLS, CULTURED; CITRIC ACID; DISEASE PROGRESSION; IRON; MUSCLE, SMOOTH, VASCULAR; OSTEOBLASTS; PHOSPHATES; RATS; VASCULAR CALCIFICATION;

EID: 84992035759     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.09.071     Document Type: Article

References (41)

1. [1] Kooman, J.P., Kotanko, P., Schols, A.M., et al. Chronic kidney disease and premature ageing. Nat. Rev. Nephrol. 10:12 (2014 Dec), 732–742.
2. [2] Vervloet, M.G., Massy, Z.A., Brandenburg, V.M., et al. Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders. Lancet Diabetes Endocrinol. 2:5 (2014 May), 427–436.
3. [3] Cozzolino, M., Ureña-Torres, P., Vervloet, M.G., et al. Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome?. Nephrol. Dial. Transpl. 29:10 (2014 Oct), 1815–1820.
4. [4] Ciceri, P., Volpi, E., Brenna, I., et al. Combined effects of ascorbic acid and phosphate on rat VSMC osteoblastic differentiation. Nephrol. Dial. Transpl. Nephrol. Dial. Transpl. 27:1 (2012 Jan), 122–127.
5. [5] Cannata-Andía, J.B., Fernández-Martín, J.L., Locatelli, F., et al. Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int. 84:5 (2013 Nov), 998–1008.
6. [6] Jamal, S.A., Vandermeer, B., Raggi, P., et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet 382:9900 (2013 Oct 12), 1268–1277.
7. [7] Negri, A.L., Ureña Torres, P.A., Iron-based phosphate binders: do they offer advantages over currently available phosphate binders?. Clin. Kidney J. 8:2 (2015 Apr), 161–167.
8. [8] Hörl, W.H., Clinical aspects of iron use in the anemia of kidney disease. J. Am. Soc. Nephrol. 18 (2007), 382–393.
9. [9] KDOQI, National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am. J. Kidney Dis. 47 (2006), S11–S145 (5 suppl 3).
10. [10] Cozzolino, M., Staniforth, M.E., Liapis, H., Finch, J., Burke, S.K., Dusso, A.S., Slatopolsky, E., Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney Int. 64:5 (2003 Nov), 1653–1661.
11. [11] Ciceri, P., Elli, F., Brenna, I., Volpi, E., Romagnoli, S., Tosi, D., Braidotti, P., Brancaccio, D., Cozzolino, M., Lanthanum prevents high phosphate-induced vascular calcification by preserving vascular smooth muscle lineage markers. Calcif. Tissue Int. 92:6 (2013 Jun), 521–530.
12. [12] Luna, L.G., Manual of Histologic Staining Methods of the Armed Forces Institute of Pathology, vol. 176, 1970, McGraw-Hill Book Company, 184.
13. [13] Jones, M., Ibels, L., Schenkel, B., Zagari, M., Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Kidney Int. 65 (2004), 757–767.
14. [14] Collins, A.J., Li, S., St Peter, W., Ebben, J., Roberts, T., Ma, J.Z., Manning, W., Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J. Am. Soc. Nephrol. 12 (2001), 2465–2473.
15. [15] Besarab, A., Resolving the paradigm crisis in intravenous iron and erythropoietin management. Kidney Int. Suppl. 101 (2006), S13–S18.
16. [16] Chen, N.X., Duan, D., O'Neill, K.D., Wolisi, G.O., Koczman, J.J., Laclair, R., Moe, S.M., The mechanisms of uremic serum-induced expression of bone matrix proteins in bovine vascular smooth muscle cells. Kidney Int. 70 (2006), 1046–1053.
17. [17] Moe, S.M., O'Neill, K.D., Duan, D., Ahmed, S., Chen, N.X., Leapman, S.B., Fineberg, N., Kopecky, K., Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int. 61 (2002), 638–647.
18. [18] Moe, S.M., Duan, D., Doehle, B.P., O'Neill, K.D., Chen, N.X., Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int. 63 (2003), 1003–1011.
19. [19] Giachelli, C.M., The emerging role of phosphate in vascular calcification. Kidney Int. 75 (2009), 890–897.
20. [20] Schlieper, G., Westenfeld, R., Brandenburg, V., Ketteler, M., Inhibitors of calcification in blood and urine. Semin. Dial. 20 (2007), 113–121.
21. [21] Zarjou, A., Jeney, V., Arosio, P., Poli, M., Antal-Szalmás, P., Agarwal, A., Balla, G., Balla, J., Ferritin prevents calcification and osteoblastic differentiation of vascular smooth muscle cells. J. Am. Soc. Nephrol. 20 (2009), 1254–1263.
22. [22] Giachelli, C.M., Vascular calcification: in vitro evidence for the role of inorganic phosphate. J. Am. Soc. Nephrol. 14 (2003), S300–S304.
23. [23] Yang, H., Curinga, G., Giachelli, C.M., Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. Kidney Int. 66 (2004), 2293–2299.
24. [24] Moe, S.M., Reslerova, M., Ketteler, M., O'neill, K., Duan, D., Koczman, J., Westenfeld, R., Jahnen-Dechent, W., Chen, N.X., Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int. 67 (2005), 2295–2304.
25. [25] Neven, E., Persy, V., Dauwe, S., De Schutter, T., De Broe, M.E., D'Haese, P.C., Chondrocyte rather than osteoblast conversion of vascular cells underlies medial calcification in uremic rats. Arterioscler. Thromb. Vasc. Biol. 30 (2010), 1741–1750.
26. [26] Sutra, T., Morena, M., Bargnoux, A.S., Caporiccio, B., Canaud, B., Cristol, J.P., Superoxide production: a procalcifying cell signalling event in osteoblastic differentiation of vascular smooth muscle cells exposed to calcification media. Free Radic. Res. 42:9 (2008 Sep), 789–797.
27. [27] Zhao, M.M., Xu, M.J., Cai, Y., Zhao, G., Guan, Y., Kong, W., Tang, C., Wang, X., Mitochondrial reactive oxygen species promote p65 nuclear translocation mediating high-phosphate-induced vascular calcification in vitro and in vivo. Kidney Int. 79:10 (2011 May), 1071–1079.
28. [28] Ha, C.M., Park, S., Choi, Y.K., Jeong, J.Y., Oh, C.J., Bae, K.H., Lee, S.J., Kim, J.H., Park, K.G., Jun do, Y., Lee, I.K., Activation of Nrf2 by dimethyl fumarate improves vascular calcification. Vasc. Pharmacol. 63:1 (2014 Oct), 29–36.
29. [29] Becs, G., Zarjou, A., Agarwal, A., Kovács, K.É., Becs, Á., Nyitrai, M., Balogh, E., Bányai, E., Eaton, J.W., Arosio, P., Poli, M., Jeney, V., Balla, J., Balla, G., Pharmacological induction of ferritin prevents osteoblastic transformation of smooth muscle cells. J. Cell Mol. Med. 20:2 (2016 Feb), 217–230.
30. [30] Dai, X.Y., Zhao, M.M., Cai, Y., Guan, Q.C., Zhao, Y., Guan, Y., Kong, W., Zhu, W.G., Xu, M.J., Wang, X., Phosphate-induced autophagy counteracts vascular calcification by reducing matrix vesicle release. Kidney Int. 83:6 (2013 Jun), 1042–1051.
31. [31] Ciceri, P., Elli, F., Cappelletti, L., Tosi, D., Braidotti, P., Bulfamante, G., Cozzolino, M., A new in vitro model to delay high phosphate-induced vascular calcification progression. Mol. Cell Biochem. 410:1–2 (2015 Dec), 197–206.
32. [32] Reynolds, J.L., Joannides, A.J., Skepper, J.N., McNair, R., Schurgers, L.J., Proudfoot, D., Jahnen-Dechent, W., Weissberg, P.L., Shanahan, C.M., Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J. Am. Soc. Nephrol. 15 (2004), 2857–2867.
33. [33] Proudfoot, D., Skepper, J.N., Hegyi, L., Bennett, M.R., Shanahan, C.M., Weissberg, P.L., Apoptosis regulates human vascular calcification in vitro: evidence for initiation of vascular calcification by apoptotic bodies. Circ. Res. 87 (2000), 1055–1062.
34. [34] Shroff, R.C., McNair, R., Figg, N., Skepper, J.N., Schurgers, L., Gupta, A., Hiorns, M., Donald, A.E., Deanfield, J., Rees, L., Shanahan, C.M., Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation 118 (2008), 1748–1757.
35. [35] Son, B.K., Kozaki, K., Iijima, K., Eto, M., Kojima, T., Ota, H., Senda, Y., Maemura, K., Nakano, T., Akishita, M., Ouchi, Y., Statins protect human aortic smooth muscle cells from inorganic phosphate-induced calcification by restoring Gas6-Axl survival pathway. Circ. Res. 98:8 (2006 Apr 28), 1024–1031.
36. [36] Sandberg, E.M., Sayeski, P.P., Jak2 tyrosine kinase mediates oxidative stress-induced apoptosis in vascular smooth muscle cells. J. Biol. Chem. 279 (2004), 34547–34552.
37. [37] Schaeffer, C., Thomassin, L., Rochette, L., Connat, J.L., Apoptosis induced in vascular smooth muscle cells by oxidative stress is partly prevented by pretreatment with CGRP. Ann. N. Y. Acad. Sci. 1010 (2003), 733–737.
38. [38] Agarwal, R., Vasavada, N., Sachs, N.G., Chase, S., Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int. 65:6 (2004 Jun), 2279–2289.
39. [39] Kuryshev, Y.A., Brittenham, G.M., Fujioka, H., Kannan, P., Shieh, C.C., Cohen, S.A., Brown, A.M., Decreased sodium and increased transient outward potassium currents in iron-loaded cardiac myocytes. Implications for the arrhythmogenesis of human siderotic heart disease. Circulation 100 (1999), 675–683.
40. [40] Hayat, A., Safety issues with intravenous iron products in the management of anemia in chronic kidney disease. Clin. Med. Res. 6 (2008), 93–102.
41. [41] Kletzmayr, J., Hörl, W.H., Iron overload and cardiovascular complications in dialysis patients. Nephrol. Dial. Transpl. 17:Suppl. 2 (2002), 25–29.